Randomized, blinded clinical study evaluating injectable autologous hair follicle secretome in patients with androgenic ...

Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between those ...

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver ...

A study finds that many patients with severe alopecia areata achieve meaningful hair regrowth after switching JAK inhibitors, ...

Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT ...

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ...

Patients with alopecia areata (AA) who do not respond to treatment with one of the three approved JAK inhibitors may get a response by switching to one of the other JAK inhibitors, a small study has ...

AbbVie said a second late-stage study of its blockbuster autoimmune drug Rinvoq hit its main goals in the autoimmune disease alopecia areata. AbbVie on Thursday said the Phase 3 study evaluating the ...

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found. The study, led by King’s College London is the largest of its kind and published in ...

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK. The event, the press release and the slides ...